Net Sales: $137.3 million in Q1 2025, up 33% from Q4 2024. Patient Growth: Over 17,000 patients on Rezdiffra by end of Q1 2025, up from 11,800 in Q4 2024. Prescriber Penetration: 70% of 6,000 top target prescribers have prescribed Rezdiffra. R&D Expenses: $44.2 million in Q1 2025, down from $71.2 million in Q1 2024.
M K Rajashekaran 16 March 2025, 08:14 AM IST With the expiry of patents for several essential medicines, the prices of key drugs, including those for diabetes, asthma, and schizophrenia, are expected to drop significantly as cheaper generic alternatives enter the market. Representational image. Thrissur: The prices of several essential medicines in India are set